M&A
News/ News/ Sales and Marketing
Pfizer bid for sickle cell drug developer GBT said to be imminent
Phil Taylor
Global Blood Therapeutics, M&A, Oxbryta, Pfizer, sickle cell disease
0 Comment
Gilead snaps up MiroBio and its checkpoint agonists for $405m
Phil Taylor
AnaptysBio, Eli Lilly, Gilead Sciences, Immunology and inflammation, M&A, MiroBio
0 Comment
Amgen splashes out on ChemoCentryx and its blockbuster hopeful
Phil Taylor
Amgen, ChemoCentryx, Immunology and inflammation, M&A, nephrology, Tavneos
0 Comment
Labcorp unveils plan to spin out clinical development business
Phil Taylor
clinical research, CRO, Labcorp, M&A, outsourcing
0 Comment
News/ News/ Sales and Marketing
Ginkgo buys Zymergen, but may shed drug discovery business
Phil Taylor
biotechnology, Ginkgo Bioworks, M&A, synthetic biology, Zymergen
0 Comment
Digital/ News/ News/ News/ Patients
Amazon ratchets up its health ambitions, buying US primary care group
Phil Taylor
Amazon, digital health, M&A, One Medical Group, telehealth, telemedicine
0 Comment
News/ News/ Sales and Marketing
Novartis faces tougher decision on Sandoz, as finances recover
Phil Taylor
biosimilars, Financial, generics, M&A, Novartis, Sandoz
0 Comment
News/ News/ News/ Oncology/ Sales and Marketing
Commission can rule on Illumina, Grail merger, says EU court
Phil Taylor
antitrust, diagnostics, European Commission, Galleri, Grail, Illumina, litigation, M&A, Oncology
0 Comment